Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. Cancelled.

2. (Currently Amended) A ~~non-tumorigenic~~ cell composition derived from embryonic stem cells, the composition comprising from 85% to 100% isolated ~~neuronal~~**neural** precursor cells, which have the ability to differentiate **in**to neuronal **cells, ~~or~~** glial cells, **or combinations thereof,** and **further comprising** from 0% to 15% primitive embryonic and non-neural cells,

the composition being obtainable by:

(a) culturing the embryonic stem cells to produce neural precursor cells[[,]];

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium[[,]];

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium[[,]]; and

(d) culturing the cells from (c) in a third growth factor-containing serum-free medium,

wherein the cells from (d) have the ability to differentiate **in**to neuronal **cells, ~~or~~** glial cells, **or combinations thereof, and**

wherein the cell composition is non-tumorigenic.

3. (Previously Presented) The cell composition according to claim 2, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

4. Cancelled.

5. Cancelled.

6. (Currently Amended) The cell composition according to claim 2, wherein **the**~~said~~ cells **of steps (c) and (d)** grow as a monolayer.

7. Cancelled.

8. (Currently Amended) The cell composition according to claim 2, comprising cells with ~~neuronal, astroglial or~~ oligodendroglial**, astroglial, or neuronal** properties, or a combination thereof.

9. (Previously Presented) The cell composition according to claim 2, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

10. (Previously Presented) The cell composition according to claim 2, wherein the embryonic stem cells are obtained from embryonic germ cells.

11. (Previously Presented) The cell composition according to claim 2, wherein the cells are mammalian cells.

12. (Previously Presented) The cell composition according to claim 11, wherein the cells are isolated from a mammal selected from the group consisting of mouse, rat, hamster, pig, cow, primate, and human.

13. (Currently Amended) The cell composition according to claim 2, wherein the **embryonic stem** cells are genetically modified.

14. Cancelled.

15. (Currently Amended) **A cell**~~Cell~~ library comprising autologous and non-autologous cells according **to** claim 47.

16. – 45. Cancelled.

46. (Previously Presented) A pharmaceutical composition comprising the precursor cells of claim 47.

47. (Currently Amended) A ~~non-tumorigenic~~ cell composition derived from embryonic stem cells,

the composition comprising from 85% to 100% isolated ~~neuronal~~**neural** precursor cells, which have the ability to differentiate **in**to neuronal **cells, ~~or~~** glial cells, **or combinations thereof,** and **further comprising** from 0% to 15% primitive embryonic and non-neural cells**, and wherein the cell composition is non-tumorigenic**.

48. (Previously Presented) The cell composition of claim 2, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

49. Cancelled.

50. (Previously Presented) The cell composition of claim 3, wherein the cell aggregates are embryoid bodies.

51. Cancelled.

52. (New) A cell composition derived from embryonic stem cells, the composition comprising from 85% to 100% isolated neural precursor cells, which have the ability to differentiate into neuronal cells, glial cells, or combinations thereof, and further comprising from 0% to 15% primitive embryonic and non-neural cells,

the composition being obtainable by:

(a) culturing the embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium; and

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres;

wherein the cells of the neural spheres have the ability to differentiate into astrogilal cells, oligodendroglial cells, neuronal cells, or combinations thereof, and

wherein the cell composition is non-tumorigenic.

53. (New) The cell composition according to claim 52, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

54. (New) The cell composition of claim 53, wherein the cell aggregates are embryoid bodies.

55. (New) The cell composition of claim 52, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

56. (New) The cell composition according to claim 52, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

57. (New) The cell composition according to claim 52, wherein the embryonic stem cells are obtained from embryonic germ cells.

58. (New) The cell composition according to claim 52, wherein the cells are mammalian cells.

59. (New) The cell composition according to claim 58, wherein the cells are isolated from a mammal selected from the group consisting of mouse, rat, hamster, pig, cow, primate, and human.

60. (New) The cell composition according to claim 52, wherein the embryonic stem cells are genetically modified.

61. (New) A cell library comprising autologous and non-autologous cells according to claim 52.

62. (New) A pharmaceutical composition comprising the precursor cells of claim 52.

63. (New) A cell composition derived from embryonic stem cells, the composition comprising from 85% to 100% isolated neural precursor cells, which have the ability to differentiate into glial cells, and further comprising from 0% to 15% primitive embryonic and non-neural cells,

the composition being obtainable by:

(a) culturing the embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium to produce neural spheres; and

(d) culturing the neural spheres from (c) in a third growth factor-containing serum-free medium to produce a monolayer of glial precursor cells,

wherein the cells of the monolayer have the ability to differentiate into glial cells, and

wherein the cell composition is non-tumorigenic.

64. (New) The cell composition according to claim 63, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

65. (New) The cell composition of claim 64, wherein the cell aggregates are embryoid bodies.

66. (New) The cell composition of claim 63, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

67. (New) The cell composition according to claim 63, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

68. (New) The cell composition according to claim 63, wherein the embryonic stem cells are obtained from embryonic germ cells.

69. (New) The cell composition according to claim 63, wherein the cells are mammalian cells.

70. (New) The cell composition according to claim 69, wherein the cells are isolated from a mammal selected from the group consisting of mouse, rat, hamster, pig, cow, primate, and human.

71. (New) The cell composition according to claim 63, wherein the cells are genetically modified.

72. (New) A cell library comprising autologous and non-autologous cells according to claim 63.

73. (New) A pharmaceutical composition comprising the precursor cells of claim 63.

74. (New) A cell library comprising autologous and non-autologous cells according to claim 2.

75. (New) A pharmaceutical composition comprising the precursor cells of claim 2.